Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | WHR1 | P49842 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 7/20 | 0.56 |
| ▸ | KDR | P35968 | 6/20 | 0.56 |
| ▸ | KDM1A | O60341 | 4/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.54 |
| ▸ | KMT5A | Q9NQR1 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25366062 | 0.90 | HTT (0.59) | HTTWHR1EGFRKDRKDM1A | |
| SCHEMBL26530735 | 0.85 | HTT (0.78) | HTTEGFRKDREHMT2KMT5A | |
| SCHEMBL20281125 | 0.84 | HTT (0.76) | HTTEGFRKDREHMT2KMT5A | |
| SCHEMBL25360755 | 0.83 | HTT (0.60) | HTTWHR1EGFRKDRKDM1A | |
| SCHEMBL13975792 | 0.83 | HTT (0.74) | HTTEGFRKDREHMT2KMT5A | |
| SCHEMBL14341613 | 0.82 | HTT (0.72) | HTTEGFRKDREHMT2KMT5A | |
| SCHEMBL17122655 | 0.81 | HTT (0.70) | HTTEGFRKDREHMT2KMT5A | |
| SCHEMBL17122647 | 0.80 | HTT (0.66) | HTTEGFRKDREHMT2APP | |
| SCHEMBL17122605 | 0.79 | HTT (0.79) | HTTEGFRKDRKDM1ARCOR1 | |
| SCHEMBL20266987 | 0.79 | APP (0.71) | HTTEGFRKDRAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | HTT 4396/4885WHR1 3876/4885EGFR 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.